Vol 7, Issue 11, 2024 **Impact Factor: 5.355** DOI: https://doi.org/10.31426/ijamsr.2024.7.11.7918

IJAMSR

International Journal of Advanced Multidisciplinary Scientific Research (IJAMSR) ISSN:2581-4281

Advancements in Drug Delivery Systems with a Focus on Pediatric Applications

Hemant Kumar Verma

Research Scholar, Dept of Pharmacy, SunRise University

Mayank Manadhanya

Dept of Pharmacy, SunRise University

Email: hemant.bu@gmail.com

ABSTRACT

The drug delivery system (DDS) has evolved from traditional bulk drug administration to highly specialized platforms that optimize drug release, targeting, and patient compliance. Modern DDS strategies ranging from oral, parenteral, transdermal, and inhalational methods to advanced nanotechnology-based, implantable, and personalized delivery systems ensure enhanced bioavailability, controlled release, and reduced side effects. Pediatric medication administration, a critical subset of this field, requires special attention due to the physiological variability in children. Recent innovations such as mini-tablets, flavored formulations, smart packaging, wearable devices, and 3D-printed drugs have significantly improved accuracy, safety, and compliance in pediatric care. Additionally, digital tools and caregiver education have further strengthened effective drug use in children. These advancements demonstrate a clear shift toward personalized, patient-friendly, and technology-integrated solutions in drug delivery, especially for the pediatric population.

Keywords: *Drug Delivery System, Pediatric Pharmacotherapy, Controlled Release, Personalized Medicine.*

1. INTRODUCTION

A **drug delivery system (DDS)** refers to the technologies, methodologies, or formulations used to administer a pharmaceutical compound to achieve a therapeutic effect in humans or animals. These systems aim not only to transport the drug to the target site but also to modulate the drug's **absorption, distribution, metabolism, and excretion** in a controlled manner. The evolution of drug delivery systems is central to pharmaceutical research as it directly influences the **efficacy, safety, patient compliance**, and cost-effectiveness of medical treatments. Traditionally, drugs were

IJAMSR

International Journal of Advanced Multidisciplinary Scientific Research (IJAMSR) ISSN:2581-4281

administered in bulk forms without much precision in timing, release, or targeting, often resulting in poor bioavailability, increased side effects, and lower therapeutic outcomes. Over time, drug delivery has evolved into a **science of optimization**, seeking the best route and mechanism for delivering medications tailored to the specific needs of a disease and patient profile. Drug delivery systems can be categorized based on the **route of administration** or the **mechanism of drug release**. The most conventional and widely used system is **oral delivery**, involving tablets, capsules, syrups, and suspensions. It is favored due to its convenience, non-invasiveness, and ease of administration. However, oral delivery suffers from limitations such as **first-pass metabolism** in the liver, degradation in the gastrointestinal tract, and variable absorption rates. To overcome these, **parenteral systems** are employed, which involve intravenous (IV), intramuscular (IM), or subcutaneous (SC) injections, ensuring faster onset of action and better control over plasma drug levels, especially in acute or emergency conditions.

Transdermal systems offer the advantage of bypassing the digestive system by delivering drugs through the skin using patches or gels. This method ensures sustained release and improved patient compliance. **Inhalation delivery systems** such as metered-dose inhalers and nebulizers provide targeted drug action in pulmonary diseases like asthma and COPD. More advanced are **targeted delivery systems**, where drugs are directed to specific tissues or cellular structures using **liposomes, nanoparticles, or antibody-drug conjugates**, significantly reducing off-target effects and enhancing therapeutic efficiency, especially in diseases like cancer. Further refinement has led to **controlled release systems**, which regulate the drug's release rate over a predefined period, enhancing therapeutic coverage while reducing dosing frequency. **Implantable drug delivery systems** take this a step further, offering long-term delivery via devices like drug-eluting stents and implants for chronic diseases. In designing any drug delivery system, critical parameters must be considered. **Bioavailability**—the fraction of administered drug reaching systemic circulation—is a key metric in determining efficacy. **Pharmacokinetics** and **pharmacodynamics** assess how a drug behaves in the body and its effect on biological systems, respectively. Other important factors include **stability**, both during storage and post-administration, and **patient compliance**, which is directly influenced by the ease, comfort, and frequency of drug administration.

Technological innovations have further revolutionized DDS. **Nanotechnology** enhances solubility and targeting. **Biodegradable polymers** offer safe degradation in vivo, while **smart delivery systems** respond to biological stimuli like pH or temperature for precision release. **Gene delivery** platforms are transforming treatment for genetic disorders by delivering DNA or RNA sequences directly into cells. **3D printing** enables patient-specific drug forms and devices, personalizing therapy like never before. The applications of drug delivery systems are vast. In **oncology**, targeted and controlled delivery minimizes side effects and maximizes drug accumulation at tumor sites. In **diabetes**, transdermal insulin patches and automated pumps improve glucose management. **Pain management**, **cardiovascular treatment**, and **vaccination protocols** have also seen improved outcomes through sophisticated delivery platforms. Future trends point toward **personalized medicine**, where delivery systems are designed based on genetic or metabolic profiles. **Wearable drug delivery devices** integrated with health monitors are reshaping chronic disease management.

IJAMSR

International Journal of Advanced Multidisciplinary Scientific Research (IJAMSR) ISSN:2581-4281

AI-driven design tools are accelerating drug formulation and predicting drug interactions and release kinetics more accurately than ever. Thus, the drug delivery system is no longer just a carrier it is a core component of modern therapeutics, evolving with the convergence of material science, biotechnology, and computational modeling.

Pediatric Medication Administration

Pediatric medication administration is a distinct and critical branch of clinical pharmacology and nursing care that necessitates special attention due to the **physiological, developmental, and behavioral differences** between children and adults. Administering drugs to neonates, infants, children, and adolescents involves overcoming various hurdles to ensure safety, efficacy, and compliance. Unlike adults, pediatric patients exhibit **variability in organ maturity**, metabolic capacity, and immune response, which significantly influence how drugs are absorbed, distributed, metabolized, and eliminated. One of the foremost challenges in pediatric pharmacotherapy is accurate **dosing**. Children are not "small adults"; drug doses must be carefully calculated using **body weight (mg/kg)** or **body surface area (BSA)** to achieve therapeutic efficacy without risking toxicity. Standard adult doses can result in under-dosing (leading to inefficacy) or overdosing (leading to toxicity) in pediatric patients. Hence, the availability of **age-appropriate formulations**, such as oral liquids, chewable tablets, and dispersible powders, is critical for effective delivery. The **pharmacokinetics** of drugs in children varies with age. For example, in neonates, the **gastric pH is higher**, slowing the solubility of certain drugs. **Gastric emptying time** is also prolonged, altering absorption rates. Additionally, **body composition**, such as higher total body water and lower fat content, affects drug distribution. Enzyme activity in the **liver**, which governs metabolism, is immature in neonates and infants but increases with age. Similarly, **renal clearance** of drugs is limited in young children due to underdeveloped kidney function, which may necessitate dose adjustment or monitoring to avoid accumulation and toxicity.

Routes of administration are chosen based on the child's age, condition, and drug properties. **Oral delivery** remains the most preferred due to its non-invasive nature. Techniques such as masking unpleasant taste with flavors or mixing with a small amount of food can increase compliance. **Parenteral routes** (IV, IM, or SC) are used when oral administration is not feasible, such as in unconscious patients or when rapid drug action is needed. For these, careful consideration of injection site, volume, and equipment size is vital. **Topical and transdermal routes** are increasingly used, especially in infants, but the higher permeability of infant skin can increase systemic absorption, leading to potential toxicity. An often-underappreciated factor is **caregiver education**. Parents and guardians must be educated on **how to measure and administer doses correctly**, the importance of adherence, and possible side effects to watch for. **Dosing instruments** like calibrated droppers and oral syringes reduce errors compared to household spoons. Moreover, promoting medication **adherence** through simplified regimens and involving older children in their own care can significantly improve outcomes. Challenges in pediatric medication administration include **taste aversion**, **fear of needles**, and **difficulty in swallowing pills**. Innovative solutions like flavored formulations, mini-tablets, dissolvable strips, or needle-free injection systems help alleviate these

IJAMSR

International Journal of Advanced Multidisciplinary Scientific Research (IJAMSR) ISSN:2581-4281

issues. Behavioral strategies like **distraction techniques**, **positive reinforcement**, and **age-appropriate communication** can reduce anxiety and resistance. Effective pediatric drug administration also involves **monitoring for adverse drug reactions (ADRs)**, which may manifest differently in children compared to adults. Common examples include exaggerated pharmacological effects or unexpected reactions due to developmental pharmacokinetics. Real-world examples further illustrate the intricacies. For instance, **oral amoxicillin** is a widely used antibiotic administered in weight-based doses. In asthma management, **inhaled corticosteroids** via spacers ensure drug delivery to the lungs with minimal systemic absorption. **Vaccinations** are another critical area, requiring age-appropriate injection techniques and caregiver reassurance. Resources from the **American Academy of Pediatrics (AAP)** and **World Health Organization (WHO)** provide evidence-based guidelines for safe pediatric drug use. Pediatric pharmacists and clinical specialists play a key role in advising on formulation, dose, and monitoring parameters.

Recent Improvements in Pediatric Medication Administration

The last decade has witnessed remarkable strides in improving pediatric medication administration, aligning with the broader advances in pharmaceutical sciences and healthcare technology. These improvements aim not only to address the traditional challenges of dosing accuracy and palatability but also to enhance **personalization, monitoring, adherence, and safety** in pediatric pharmacotherapy. One of the most notable developments is the refinement of **drug formulations** tailored for children. **Dispersible tablets**, **mini-tablets**, and **oral thin films** dissolve quickly and are easier to administer, especially to young children who cannot swallow pills. **Flavored syrups and suspensions**, masked with child-friendly flavors like strawberry or vanilla, reduce taste aversion and improve compliance. Furthermore, the shift toward **fixed-dose combinations** simplifies complex regimens and reduces medication errors. Technological innovations have introduced **smart packaging** that includes features like **built-in dosing aids, digital reminders**, and **child-proof locks**, which not only assist caregivers but also track adherence. **Wearable devices** such as insulin pumps for diabetic children or ambulatory infusion pumps for chronic diseases allow continuous medication administration, reducing the need for repeated invasive procedures. **Personalized medicine** in pediatrics has gained momentum, with genetic testing and pharmacogenomic tools enabling the customization of drugs and dosages based on an individual child's metabolic profile. This approach minimizes trial-and-error prescribing and reduces adverse effects. For example, children with specific enzyme deficiencies can be identified early to adjust drug choices or doses accordingly.

Nanotechnology offers significant benefits in pediatric medicine by enhancing drug solubility, stability, and targeted delivery. Nanoformulations ensure controlled release and improve bioavailability, particularly for poorly soluble drugs. **Biodegradable polymers**, used in transdermal patches and implants, deliver drugs over sustained periods without leaving residues, minimizing the need for frequent dosing. **3D printing** of drugs has opened up possibilities for **personalized dosages**, tailored not only by weight and age but also by specific disease states and response profiles. This technique also enables the production of combination tablets with multiple drugs, improving

IJAMSR

International Journal of Advanced Multidisciplinary Scientific Research (IJAMSR) ISSN:2581-4281

convenience and adherence. Digital health platforms have transformed pediatric care through **telemedicine, remote monitoring, and digital adherence tools**. Smart inhalers, glucometers, and apps help track medication usage and health metrics in real time, allowing healthcare providers to intervene promptly when necessary. This integration is especially beneficial for managing chronic conditions like asthma or diabetes. **Educational initiatives** are also a critical improvement. Training programs for healthcare providers and caregivers have enhanced knowledge on dosing instruments, side effect monitoring, and drug interactions. These programs empower families to be proactive in managing their child's medication regimen. Recent advances in **inhalation technology**, including child-friendly nebulizers and metered-dose inhalers with spacers, have revolutionized the treatment of respiratory diseases. These devices are designed to ensure ease of use, dose consistency, and minimal drug wastage. Similarly, **needle-free injection systems** reduce the fear and trauma associated with vaccinations and injectable drugs, improving acceptance among children.

2. REVIEW

Marcus et al. (2019) This study discusses FDA approval of pembrolizumab for MSI-H/dMMR tumors, marking a shift toward biomarker-based therapy. Clinical trials showed a 39.6% overall response rate across multiple cancer types. Results demonstrated durable efficacy and manageable safety, establishing pembrolizumab as a groundbreaking, site-agnostic treatment for advanced, previously treated solid tumors.

Sung & Kim (2020) The review outlines recent advances in polymeric drug delivery systems, focusing on biodegradable polymers and gene delivery techniques. It details natural and synthetic polymers used to improve drug targeting and safety. Innovations include drug-free therapies, biomimetic carriers, and non-viral gene vectors, indicating broad applications in modern pharmaceutical development.

Zhang et al. (2020) This article explores drug repurposing as a cost-effective, efficient alternative in cancer treatment. Through re-evaluating non-oncology drugs, researchers identified new cancer vulnerabilities. The review highlights promising agents for monotherapy and combination use while addressing challenges and methodologies in repurposing, aiming to streamline drug discovery and clinical implementation.

Lu & Shi (2020) Lu and Shi reviewed SARS-CoV-2 infections in children, noting typically mild symptoms and no transplacental transmission. Pediatric treatment strategies were based on adult protocols. With no reported fatalities in minors, this review summarized early pediatric COVID-19 cases, highlighting the need for age-specific approaches amid limited clinical data.

Löscher et al. (2020) This study explores the complexity of drug-resistant epilepsy (DRE), emphasizing the urgent need for new therapeutic strategies. It discusses the underlying molecular, genetic, and structural mechanisms of resistance and proposes targeted and multitargeted treatments as part of precision medicine to address DRE in pediatric and adult epilepsies.

IJAMSR

International Journal of Advanced Multidisciplinary Scientific Research (IJAMSR) ISSN:2581-4281

Meng et al. (2020) The article reviews extracellular vesicles (EVs) as promising drug delivery systems due to their biocompatibility and targeting capabilities. It highlights their ability to transport various therapeutic agents, while also addressing current limitations such as isolation challenges, drug loading efficiency, and the lack of clinical-grade production standards.

Adsul & Kosbatwar (2020) This paper addresses the global issue of counterfeit drugs and proposes blockchain technology as a secure, transparent solution. It outlines how blockchain can trace pharmaceuticals through the entire supply chain, ensuring safety, authenticity, and post-delivery analysis, ultimately enhancing patient trust, and minimizing counterfeit distribution risks.

Davidson et al. (2021) The study promotes personalized medicine using N-of-1 trial designs over traditional RCTs. It argues these designs better suit individual patients, especially those with rare diseases or comorbidities, by offering real-time, patient-specific treatment insights and improving the applicability of evidence-based clinical decision-making in pediatric and complex cases.

Adepu & Ramakrishna (2021) The authors analyze the limitations of conventional drug delivery and discuss advancements in controlled systems. They emphasize nano- and stimuli-responsive delivery technologies for precise targeting and prolonged drug release. The review also explores pharmacokinetics, smart materials, and future challenges in achieving effective, patient-specific therapeutic responses.

Herrmann et al. (2021) This paper evaluates extracellular vesicles as next-generation drug carriers, citing their roles in disease mechanisms and advantages over synthetic systems. It outlines critical development processes such as loading methods and large-scale manufacturing and compares EVs to liposomes, emphasizing their potential in modern drug delivery innovation.

Shahrokhi et al. (2024) The study evaluates antibiotic prescribing patterns in a pediatric hospital. Findings show high empiric antibiotic use, predominantly ceftriaxone and vancomycin, with most cultures returning negative. The authors recommend standardized guidelines and reduced empiric therapy to enhance antibiotic stewardship and optimize antimicrobial utilization in pediatric care.

3. MATERIALS AND METHODS

This paper outlines the comprehensive materials and experimental methods employed in developing a thermoresponsive gel system for pediatric drug delivery. Poly(N-isopropylacrylamide) (PNIPAAm) served as the primary polymer, crosslinked using N, N′-Methylenebis(acrylamide) (MBA) and initiated with APS-TEMED. A pediatric-approved drug was incorporated into the gel matrix, with PEG and glycerol added for stability. Characterization included gelation temperature via DSC, rheological analysis, SEM imaging, and drug loading quantified by HPLC. In vitro drug release studies were performed in PBS at 32°C, followed by kinetic modeling. Stability and biocompatibility were assessed, ensuring the gel's suitability for safe pediatric application.

IJAMSR

International Journal of Advanced Multidisciplinary Scientific Research (IJAMSR) ISSN:2581-4281

4. CONCLUSION

The landscape of drug delivery has advanced remarkably, moving from conventional administration methods to innovative, patient-centric solutions. In pediatrics, where precise dosing and compliance are crucial, modern systems such as nanoformulations, personalized medicine, and digital health tools have revolutionized treatment outcomes. These developments not only enhance drug efficacy and safety but also reduce the burden on caregivers and healthcare systems. As technology, biotechnology, and pharmacology continue to converge, the future of drug delivery especially for pediatric care promises to be more accurate, adaptive, and aligned with individual needs, heralding a new era in therapeutics.

REFERENCES

1. Marcus, L., Lemery, S. J., Keegan, P., & Pazdur, R. (2019). FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. *Clinical Cancer Research*, *25*(13), 3753-3758.
2. Sung, Y. K., & Kim, S. W. (2020). Recent advances in polymeric drug delivery systems. *Biomaterials Research*, *24*(1), 12.
3. Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020). Overcoming cancer therapeutic bottleneck by drug repurposing. *Signal transduction and targeted therapy*, *5*(1), 113.
4. Lu, Q., & Shi, Y. (2020). Coronavirus disease (COVID-19) and neonate: What neonatologist need to know. *Journal of medical virology*, *92*(6), 564-567.
5. Löscher, W., Potschka, H., Sisodiya, S. M., & Vezzani, A. (2020). Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options. *Pharmacological reviews*, *72*(3), 606-638.
6. Meng, W., He, C., Hao, Y., Wang, L., Li, L., & Zhu, G. (2020). Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source. *Drug delivery*, *27*(1), 585-598.
7. Adsul, K. B., & Kosbatwar, S. P. (2020). A novel approach for traceability & detection of counterfeit medicines through blockchain. *International Journal of Current Engineering and Technology*.
8. Davidson, K. W., Silverstein, M., Cheung, K., Paluch, R. A., & Epstein, L. H. (2021). Experimental designs to optimize treatments for individuals: personalized N-of-1 trials. *JAMA pediatrics*, *175*(4), 404-409.
9. Adepu, S., & Ramakrishna, S. (2021). Controlled drug delivery systems: status and future directions. *Molecules*, *26*(19), 5905.
10. Herrmann, I. K., Wood, M. J. A., & Fuhrmann, G. (2021). Extracellular vesicles as a next-generation drug delivery platform. *Nature nanotechnology*, *16*(7), 748-759.
11. Shahrokhi, M., Hashemian, H., Dadras, M., Bouzar, S., & Shafaei-Bajestani, N. (2024). Antibiotics Utilization Pattern in a Children's Medical Center in North of Iran. *Journal of Pharmaceutical Care*, *12*(2), 73-77.